Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Nuclear Medicine

Free Subscription Articles published in Ann Neurol Retrieve available abstracts of 48 articles: HTML format

Single Articles

October 2026
1. LOW A, Gunter JL, Hu M, Raghavan S, et al
   Perivascular Spaces as Determinants of Amyloid, Tau, and Vascular Biomarker Progression.
   Ann Neurol. 2026;100:695-708.
   PubMed     Abstract available
   
   
   September 2026
2. LIM S, Lee Y, Yun CS, Kim K, et al
   Change in Amyloid-beta Deposition and Diffusion Tensor Image Analysis along the Perivascular Space Index in Incident Neurodegenerative Disease.
   Ann Neurol. 2026;100:559-571.
   PubMed     Abstract available
   
   
   August 2026
3. JIANG M, Lan G, Zhu J, Zhang L, et al
   Cross-Sectional and Longitudinal Diagnostic Performance of Plasma p-tau217 and p-tau217/Abeta42 in Alzheimer's Disease.
   Ann Neurol. 2026 Aug 14. doi: 10.1002/ana.78322.
   PubMed     Abstract available
   
   
   May 2026
4. JIANG X, O'Bryant SE, Rissman RA, Johnson LA, et al
   Multimorbidity and Associations with Cognition and Alzheimer's Disease Biomarkers.
   Ann Neurol. 2026 May 4. doi: 10.1002/ana.78238.
   PubMed     Abstract available
   
   
   March 2026
5. PEJHAN S, Budhram A, Hammond R, Zhang Q, et al
   Cerebral Amyloidoma: An Update Following "Fixation Duress" on PET.
   Ann Neurol. 2026 Mar 24. doi: 10.1002/ana.78209.
   PubMed    
   
   
   
6. FRASER JA, Romsa JG, Budhram A, Li CMF, et al
   Reply to "Cerebral Amyloidoma: An Update Following 'Fixation Duress' on PET".
   Ann Neurol. 2026 Mar 23. doi: 10.1002/ana.78210.
   PubMed    
   
   
   
7. BROWN CA, Cousins KAQ, Korecka M, McGrew E, et al
   Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease Using PET and Plasma Biomarkers.
   Ann Neurol. 2026 Mar 15. doi: 10.1002/ana.78194.
   PubMed     Abstract available
   
   
   January 2026
8. CANOVAS R, Cox T, Dore V, Bourgeat P, et al
   When Does Alzheimer's Disease Start? Plasma Abeta42/40 Assays Show Steep Changes at Abeta-PET Centiloid 15, Mean Age of 66 Years.
   Ann Neurol. 2026 Jan 26. doi: 10.1002/ana.78163.
   PubMed     Abstract available
   
   
   
9. MABOUDIAN SA, Fonseca CS, Martersteck AC, Chao Y, et al
   Tau Pathology in Alzheimer's Disease Uniquely Affects Sulcal Depths.
   Ann Neurol. 2026 Jan 24. doi: 10.1002/ana.78166.
   PubMed     Abstract available
   
   
   
10. FAN Z, Searle G, Rizzo G, Albani J, et al
    Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine Scale.
    Ann Neurol. 2026 Jan 20. doi: 10.1002/ana.78116.
    PubMed     Abstract available
    
    
    
11. FABBRI M, Del Campo N, Meissner WG, Rousseau V, et al
    Disease Progression in Multiple System Atrophy: The ASPIRE Multi-Modal Biomarker Study.
    Ann Neurol. 2026;99:96-113.
    PubMed     Abstract available
    
    
    December 2025
12. BACHMANN D, Wybitul M, Studer S, Saake A, et al
    Protective Effects of Socioeconomic Status and Lifestyle on Amyloid- and White Matter Hyperintensity-Related Longitudinal Brain Atrophy and Cognitive Decline.
    Ann Neurol. 2025;98:1222-1236.
    PubMed     Abstract available
    
    
    September 2025
13. ABDELMOITY O, Wisch JK, Kennedy JT, Goyal M, et al
    Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease.
    Ann Neurol. 2025 Sep 22. doi: 10.1002/ana.78002.
    PubMed     Abstract available
    
    
    
14. GRAFF-RADFORD J, Syrjanen JA, Vemuri P, Lowe VJ, et al
    Predictive Value of Plasma Biomarkers in Tau-PET Transitions.
    Ann Neurol. 2025 Sep 10. doi: 10.1002/ana.78003.
    PubMed     Abstract available
    
    
    
15. BUCKLEY RF, Scott M, McGrath ER, Coughlan G, et al
    Midlife Steroid-Binding Globulin Levels and In Vivo Neuroimaging Measures of Tau in Older Men and Women.
    Ann Neurol. 2025;98:524-532.
    PubMed     Abstract available
    
    
    August 2025
16. LEON KE, Rauschecker AM, Chow FC
    Use of FDG-PET in Balamuthia mandrillaris Amebic Encephalitis.
    Ann Neurol. 2025 Aug 1. doi: 10.1002/ana.70012.
    PubMed    
    
    
    June 2025
17. KIM DJ, Lim M, Nascimento TD, Porreca F, et al
    mu-Opioid Receptor Dynamics in the Parameningeal Tissue During Migraine Attacks.
    Ann Neurol. 2025 Jun 26. doi: 10.1002/ana.27289.
    PubMed     Abstract available
    
    
    
18. MILA-ALOMA M, Tosun D, Schindler SE, Hausle I, et al
    Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks.
    Ann Neurol. 2025 Jun 20. doi: 10.1002/ana.27285.
    PubMed     Abstract available
    
    
    
19. IAZZOLINO B, Palumbo F, Moglia C, Manera U, et al
    Frequency and Early Predictors of Cognitive Deterioration in Amyotrophic Lateral Sclerosis: A Longitudinal Population-Based Study.
    Ann Neurol. 2025;97:1122-1133.
    PubMed     Abstract available
    
    
    May 2025
20. BRAUN AS, Satoh R, Pham NTT, Singh-Reilly N, et al
    Machine Learning Models of Voxel-Level [(18)F] Fluorodeoxyglucose Positron Emission Tomography Data Excel at Predicting Progressive Supranuclear Palsy Pathology.
    Ann Neurol. 2025 May 30. doi: 10.1002/ana.27265.
    PubMed     Abstract available
    
    
    April 2025
21. SLINGERLAND S, van der Zee S, Carli G, Slomp AC, et al
    Cholinergic Degeneration and Cognitive Function in Early GBA1-Related Parkinson's Disease.
    Ann Neurol. 2025 Apr 16. doi: 10.1002/ana.27248.
    PubMed     Abstract available
    
    
    
22. LUO C, Nguyen TN, Li R, Tao C, et al
    Computed Tomography Perfusion Parameters: A Potential Tool for Treatment Selection in Basilar Artery Occlusion.
    Ann Neurol. 2025 Apr 2. doi: 10.1002/ana.27214.
    PubMed     Abstract available
    
    
    
23. BROWN EG, Chahine LM, Siderowf A, Gochanour C, et al
    Staged Screening Identifies People with Biomarkers Related to Neuronal Alpha-Synuclein Disease.
    Ann Neurol. 2025;97:730-740.
    PubMed     Abstract available
    
    
    March 2025
24. DZIALAS V, Bischof GN, Mollenhoff K, Drzezga A, et al
    Dopamine Transporter Imaging as Objective Monitoring Biomarker in Parkinson's Disease.
    Ann Neurol. 2025 Mar 27. doi: 10.1002/ana.27223.
    PubMed     Abstract available
    
    
    
25. LAGARDE J, Maiti P, Schonhaut DR, Blazhenets G, et al
    Amyloid PET in Sporadic Early- Versus Late-Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts.
    Ann Neurol. 2025 Mar 17. doi: 10.1002/ana.27233.
    PubMed     Abstract available
    
    
    
26. ARRIOLA-INFANTE JE, Morcillo-Nieto AO, Zsadanyi SE, Franquesa-Mullerat M, et al
    Regional Brain Metabolism across the Alzheimer's Disease Continuum in Down Syndrome.
    Ann Neurol. 2025 Mar 14. doi: 10.1002/ana.27226.
    PubMed     Abstract available
    
    
    February 2025
27. CANOSA A, Manera U, Vasta R, Zocco G, et al
    Brain Metabolic Features of FUS-ALS: A 2-[(18)F]FDG-PET Study.
    Ann Neurol. 2025 Feb 20. doi: 10.1002/ana.27201.
    PubMed     Abstract available
    
    
    
28. KEUM M, Byun MS, Yi D, Ahn H, et al
    The Use of Antihypertensive Medication and In Vivo Alzheimer's Disease Pathology.
    Ann Neurol. 2025 Feb 17. doi: 10.1002/ana.27204.
    PubMed     Abstract available
    
    
    January 2025
29. LI J, Chen D, Tang Y, Chen Z, et al
    Synaptic Density Reductions in MSA: A Potential Biomarker Identified Through [(18)F]SynVesT-1 PET Imaging.
    Ann Neurol. 2025 Jan 19. doi: 10.1002/ana.27179.
    PubMed     Abstract available
    
    
    December 2024
30. KIM N, Ryu WS, Ha SY, Kim JY, et al
    Optimal Cerebral Blood Flow Thresholds for Ischemic Core Estimation Using Computed Tomography Perfusion and Diffusion-Weighted Imaging.
    Ann Neurol. 2024 Dec 26. doi: 10.1002/ana.27169.
    PubMed     Abstract available
    
    
    
31. BRIER MR, Judge B, Ying C, Salter A, et al
    Increased White Matter Aerobic Glycolysis in Multiple Sclerosis.
    Ann Neurol. 2024 Dec 23. doi: 10.1002/ana.27165.
    PubMed     Abstract available
    
    
    October 2024
32. ENGELS-DOMINGUEZ N, Riphagen JM, Van Egroo M, Koops EA, et al
    Lower Locus Coeruleus Integrity Signals Elevated Entorhinal Tau and Clinical Progression in Asymptomatic Older Individuals.
    Ann Neurol. 2024;96:650-661.
    PubMed     Abstract available
    
    
    September 2024
33. MUTIMER CA, Mujanovic A, Kaesmacher J, Churilov L, et al
    Comparison of Perfusion Imaging Definitions of the No-Reflow Phenomenon after Thrombectomy-What Is the Best Perfusion Imaging Definition?
    Ann Neurol. 2024 Sep 3. doi: 10.1002/ana.27073.
    PubMed     Abstract available
    
    
    
34. BRUMBERG J, Blazhenets G, Buhler S, Fostitsch J, et al
    Cerebral Glucose Metabolism Is a Valuable Predictor of Survival in Patients with Lewy Body Diseases.
    Ann Neurol. 2024;96:539-550.
    PubMed     Abstract available
    
    
    August 2024
35. BITZER F, Walger L, Bauer T, Schulte F, et al
    Higher Validity, Lower Radiation: A New Ictal Single-Photon Emission Computed Tomography Framework.
    Ann Neurol. 2024 Aug 21. doi: 10.1002/ana.27061.
    PubMed     Abstract available
    
    
    
36. HIRATA K, Matsuoka K, Tagai K, Endo H, et al
    In Vivo Assessment of Astrocyte Reactivity in Patients with Progressive Supranuclear Palsy.
    Ann Neurol. 2024;96:247-261.
    PubMed     Abstract available
    
    
    June 2024
37. SOLEIMANI-MEIGOONI DN, Smith R, Provost K, Lesman-Segev OH, et al
    Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study.
    Ann Neurol. 2024 Jun 18. doi: 10.1002/ana.27008.
    PubMed     Abstract available
    
    
    May 2024
38. SAARINEN EK, Kuusimaki T, Lindholm K, Niemi K, et al
    Dietary Caffeine and Brain Dopaminergic Function in Parkinson Disease.
    Ann Neurol. 2024 May 20. doi: 10.1002/ana.26957.
    PubMed     Abstract available
    
    
    
39. LAN G, Chen X, Yang J, Sun P, et al
    Microglial Reactivity Correlates with Presynaptic Loss Independent of beta-Amyloid and Tau.
    Ann Neurol. 2024;95:917-928.
    PubMed     Abstract available
    
    
    April 2024
40. GARCIA-CORDERO I, Anastassiadis C, Khoja A, Morales-Rivero A, et al
    Evaluating the Effect of Alzheimer's Disease-Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy.
    Ann Neurol. 2024 Apr 5. doi: 10.1002/ana.26930.
    PubMed     Abstract available
    
    
    March 2024
41. ARNALDI D, Mattioli P, Raffa S, Pardini M, et al
    Presynaptic Dopaminergic Imaging Characterizes Patients with REM Sleep Behavior Disorder Due to Synucleinopathy.
    Ann Neurol. 2024 Mar 11. doi: 10.1002/ana.26902.
    PubMed     Abstract available
    
    
    
42. PAPP KV, Jutten RJ, Soberanes D, Weizenbaum E, et al
    Early Detection of Amyloid-Related Changes in Memory among Cognitively Unimpaired Older Adults with Daily Digital Testing.
    Ann Neurol. 2024;95:507-517.
    PubMed     Abstract available
    
    
    February 2024
43. LI Y, Yen D, Hendrix RD, Gordon BA, et al
    Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26891.
    PubMed     Abstract available
    
    
    
44. CHEN X, Toueg TN, Harrison TM, Baker SL, et al
    Regional Tau Deposition Reflects Different Pathways of Subsequent Neurodegeneration and Memory Decline in Cognitively Normal Older Adults.
    Ann Neurol. 2024;95:249-259.
    PubMed     Abstract available
    
    
    December 2023
45. BONOMI S, Lu R, Schindler SE, Bui Q, et al
    Relationships of Cognitive Measures with Cerebrospinal Fluid but not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals.
    Ann Neurol. 2023 Dec 1. doi: 10.1002/ana.26838.
    PubMed     Abstract available
    
    
    November 2023
46. CHUN MY, Chung SJ, Kim SH, Park CW, et al
    Hippocampal Perfusion Affects Motor and Cognitive Functions in Parkinson's Disease: An Early-Phase (18) F-FP-CIT PET Study.
    Ann Neurol. 2023 Nov 14. doi: 10.1002/ana.26827.
    PubMed     Abstract available
    
    
    October 2023
47. ZHENG L, Rubinski A, Dennecke J, Luan Y, et al
    Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer's Disease.
    Ann Neurol. 2023 Oct 14. doi: 10.1002/ana.26818.
    PubMed     Abstract available
    
    
    July 2023
48. PISANI L, Haussen DC, Mohammaden M, Perry da Camara C, et al
    Comparison of CT Perfusion Software Packages for Thrombectomy Eligibility.
    Ann Neurol. 2023 Jul 25. doi: 10.1002/ana.26748.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Nuclear Medicine is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum